|
gptkbp:instanceOf
|
benzodiazepine
sedative-hypnotic drug
|
|
gptkbp:ATCCode
|
N05CA06
|
|
gptkbp:brand
|
gptkb:Seconal
|
|
gptkbp:CASNumber
|
76-73-9
|
|
gptkbp:category
|
benzodiazepine
anticonvulsant
hypnotic
|
|
gptkbp:chemicalFormula
|
C12H18N2O3
|
|
gptkbp:color
|
white (as powder)
|
|
gptkbp:contraindication
|
porphyria
severe respiratory insufficiency
history of addiction
|
|
gptkbp:discoveredBy
|
gptkb:Donalee_L._Tabern
gptkb:Ernest_H._Volwiler
|
|
gptkbp:discoveredIn
|
1928
|
|
gptkbp:eliminationHalfLife
|
15-40 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:first_marketed
|
1934
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Secobarbital
|
|
gptkbp:IUPACName
|
5-allyl-5-(1-methylbutyl)barbituric acid
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABAA receptor
|
|
gptkbp:medicalUse
|
anticonvulsant
treatment of insomnia
preoperative sedation
|
|
gptkbp:meltingPoint
|
145-146°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
226.28 g/mol
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
5007
5193
|
|
gptkbp:riskFactor
|
addiction
overdose
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
rectal
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
respiratory depression
dependence
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:synonym
|
gptkb:Seconal_Sodium
gptkb:secobarbital_sodium
|
|
gptkbp:UNII
|
K3W5F2G96A
|
|
gptkbp:used_in
|
lethal injection (in some jurisdictions)
physician-assisted suicide (in some jurisdictions)
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
|
|
gptkbp:bfsLayer
|
6
|